Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Han, Baohui; Li, Kai; Wang, Qiming; Zhang, Li; Shi, Jianhua; Wang, Zhehai; Cheng, Ying; He, Jianxing; Shi, Yuankai; Zhao, Yizhuo; Yu, Hao; Zhao, Yang; Chen, Weiqiang; Luo, Yi; Wu, Lin; Wang, Xiuwen; Pirker, Robert; Nan, Kejun; Jin, Faguang; Dong, Jian; Li, Baolan; Sun, Yan

doi:10.1001/jamaoncol.2018.3039

Public

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Published in JAMA Oncology • Aug 9, 2018

Authors:

Baohui Han

Kai Li

Qiming Wang

Abstract

Importance: Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the drug's efficacy i...

Subject

Medicine

Internal medicine

Clinical endpoint

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!